WCN26-6819 LONG-TERM STABILIZATION OF KIDNEY FUNCTION REGARDLESS OF BASELINE eGFR AND UPCR IN PATIENTS WITH IgA NEPHROPATHY: SUBGROUP ANALYSES FROM THE ZIGAKIBART PHASE I/II TRIAL

Read full text Summarise with VIRAT
Authors: Jonathan Barratt, Eun Young Lee, Hamid Moradi, William T. Smith, Cong Lin, Laura Ann Kooienga
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Zigakibart is an investigational, humanized monoclonal antibody that blocks A PRoliferation-Inducing Ligand (APRIL), a cytokine contributing to pathogenic galactose-deficient IgA1 (Gd-IgA1) production, the initiating event in IgA nephropathy (IgAN). ADU-CL-19 is an ongoing Phase I/II trial (NCT03945318) evaluating the safety and efficacy of zigakibart in patients (pts) with IgAN. We aimed to evaluate changes in long-term kidney function in subgroups defined by baseline estimated glomerular filtration rate (eGFR) and urine protein–creatinine ratio (UPCR).

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106282–106282
Publication date
25 March 2026
Language
EN